Articles On Noxopharm (ASX:NOX)

The Noxopharm Ltd (ASX: NOX) share price has started the week in a positive fashion. At one stage today the clinical-stage drug development company’s shares were up as much as 8% to 54 cents. The Noxopharm share price has since pulled back...

05 Nov 2020 - Clinical-stage drug development company Noxopharm Limited (ASX:NOX) has partnered with Hudson Institute of Medical Research and a collaboration with The Australian Na…

Burgeoning medtech company Noxopharm (ASX: NOX) is making strides in the effort race to find a treatment for COVID-19. The Sydney-based clinical-stage drug development company has filled the first two cohorts for its trial of Veyonda, an...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the final patient has completed treatment in the LuPIN study.

Australian biotech, Noxopharm Limited (ASX:NOX) has announced an important milestone with formal approval for immediate initiation of Veyonda®’s clinical trial in COVID-19 patients in Europe. Following the key update, the Company’s...

Clinical-stage drug development player, Noxopharm Limited (ASX:NOX) has recently announced peer-reviewed publication of the LuPIN trial data in the international journal, European Urology Oncology. According to Noxopharm, the publication o...

New important pre-clinical data from two independent laboratories has validated the potential of Noxopharm Limited’s (ASX:NOX) idronoxil (active ingredient in Veyonda®) to restore the cancer-fighting immune function within ‘COLD&rsquo.....

New important pre-clinical data from two independent laboratories has validated the potential of Noxopharm Limited’s (ASX:NOX) idronoxil (active ingredient in Veyonda®) to restore the cancer-fighting immune function within ‘COLD&rsquo.....

The Noxofarm Ltd (ASX: NOX) share price soared after positive results regarding its cancer treatment drug, Veyonda, were released this morning. The immuno-oncology drug development company saw its share price rise 12% to 37 cents on the ne...

Noxopharm Limited (ASX:NOX) is trading ~5 per cent higher (as at 12:01 PM AEST) following the release of its Corporate Presentation for the Reach Markets Virtual Event. Noxopharm is focused on arguably the biggest prize in the pharma indus...

Nyrada (ASX: NYR) has received “encouraging” results from a lab-based cholesterol-lowering study, for the drug it hopes to use to treat hypercholesterolemia — or high cholesterol. The preclinical study used healthy donor human white blood c...

Noxopharm (ASX:NOX) has announced the commencement of its NOXCOVID clinical program with a planned phase one trial in Europe.

Australian clinical stage drug developer, Noxopharm Limited (ASX:NOX) notified in its latest update the commencement of NOXCOVID clinical trial program in Europe, focusing on safety and proof-of principle endpoints of Veyonda® as a potentia...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Summary Noxopharm presented two sets of clinical data concerning the development of Veyonda® as a treatment for end-stage prostate cancer at ASCO 2020 Annual Meeting. Highly encouraging interim data from the Phase 1b/2a LuPIN clinical t...

Noxopharm (ASX: NOX) has updated on its presentation of two sets of clinical trial data relating to the development of NOX66 (Veyonda) as a treatment of end-stage cancer.

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

COVID-19 vaccines are driving markets but treatments are where most people believe a solution to the pandemic lies. However, use of the two most famous treatments to date — Gilead Sciences’ HIV drug remdesivir and US President Donald Trump’...

Marking a step forward, clinical-stage drug development company Noxopharm (ASX:NOX) has lodged a pre-IND (Investigational New Drug) submission with the U.S. Food and Drug Administration (FDA) for a Veyonda® clinical trial in COVID-19 (SARS-...

Noxopharm (ASX:NOX) has lodged a pre-Investigational New Drug (pre-IND) submission with the US FDA for a clinical trial of its Veyonda in patients with COVID-19 infection.

Shares in Noxopharm Ltd (ASX:NOX) traded more than 40% higher on Tuesday afternoon after the company received advice from the US Food and Drug Administration (FDA) that it should lodge a pre-Investigational New Drug (pre-IND) submission for...

Noxopharm (ASX:NOX) has announced a $7.9 million capital raise its says will go towards progressing its oncology programs as well as its recent move into infection.

Our summary of Noxopharm Ltd's recent announcement What's happened? Noxopharm Limited (ASX:NOX) announces it will undertake a 1 for 2.5 fully underwritten, pro-rata entitlement offer of new fully paid ordinary shares at an Offer Price of $0...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve keen keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Biotech company Noxopharm Limited (ASX:NOX) possesses an exciting new potential treatment for end-stage prostate cancer as suggested by the latest radiographic review of DARRT-1 clinical study, supporting the Company’s belief in the anti-ca...

In a new development, clinical-stage oncology drug development player Noxopharm Limited (ASX:NOX) has confirmed that an isoflavonoid drug candidate has passed the proof-of-principle test for its brain cancer program in laboratory studies, p...

Noxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical study and says it shows a major benefit from a combination of Veyonda and low-dose radiotherapy.

Our summary of Noxopharm Ltd's recent announcement What's happened? Noxopharm Limited (ASX:NOX) today has released details of the radiographic review of its DARRT-1 clinical study. What are the key highlights? The review shows a major be...

Clinical-stage Australian oncology drug development player Noxopharm (ASX:NOX) has revealed that the active ingredient in Veyonda® - idronoxil, blocks the STING (Stimulator of Interferon Genes) signalling pathway associated with the type of...

Biotech company Noxopharm (ASX: NOX) will seek approval from the US Food and Drug Administration for a clinical study involving its end-stage prostate cancer drug Veyonda on early-stage COVID-19 patients with the aim of blocking the progres...

Noxopharm (ASX:NOX) is the latest biotech to announce it will test its drug against COVID-19. So how exactly does an anti-prostate cancer drug work for COVID-19? Noxopharm says it is all about one signalling pathway — the STING (Stimulator...

Noxopharm (NOX:ASX) has announced the active ingredient of its investigational therapy Veyonda - idronoxil - could block the hyper-inflammation stemming from the infection that is believed responsible for deaths in patients with COV...

Australian oncology drug development company Noxopharm (ASX:NOX), along with the Hudson Institute of Medical Research in Melbourne, has identified anti-inflammatory properties of idronoxil, consistent with reducing a ‘cytokine storm’ whic.....

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Noxopharm (ASX: NOX) is the latest small cap to reveal it has a potential COVID-19 treatment, after it reported this morning its advanced idronoxil drug could block an excessive inflammatory response believed to be responsible for many COVI...

Australian clinical stage drug development company Noxopharm Limited (ASX:NOX) recently announced a significant milestone, that its potentially transformative anti-cancer drug candidate Veyonda® has been awarded first allowed patent applica...

Noxopharm (ASX:NOX) has announced that the last patient has been enrolled and safely dosed in the ongoing LuPIN Phase 1/2 clinical trial being conducted by St Vincent’s Hospital Sydney.

CEO Graham Kelly PhD said, “Bringing Veyonda to market for late-stage prostate cancer remains our commercial imperative. This IND grant for a less common cancer type contributes to that overall commercial objective in several ways."...

Mirroring the wider market, many of the small cap IPOs completed so far in 2020 have white-knuckled their way through the opening months of the new decade. Only two – COSOL and Cobre – made solid gains. The rest bounced around like a House...

Latest LuPIN Trial Interim Results and an Alliance with Oncology Services Provider, GenesisCare Further Enhance Veyonda®’s Potential Commercial and Shareholder Value  Australian clinical-stage drug development company Noxopharm Limite...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Noxopharm (ASX:NOX) has announced a new clinical alliance with oncology services provider GenesisCare to offer a compassionate access program with its novel lead product candidate, Veyonda.

Nyrada was established in 2017 to advance the non-oncology assets developed by Noxopharm, leaving Noxopharm free to concentrate on the development of Veyonda.

Sydney biotech company Nyrada has made its debut on the ASX in the first float of the year following an $8.5 million initial public offering.

It was a solid debut for drug manufacturer Nyrada (ASX:NYR) on the ASX this morning. Nyrada raised $8.5m and opened its first session 52.5 per cent higher than its 20c IPO price, hitting an early peak of 30.5c.   Nyrada is a spin off of f...

Following an oversubscribed IPO, Noxopharm’s (NOX) U.S. spin-off Nyrada has listed on the ASX under the code NYR Post-listing, Noxopharm will hold an almost 27 per cent shareholding in Nyrada Nyrada was established in 2017 to help Noxoph...

Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc experienced strong demand in its initial public offering and will now make its ASX debut today after successfully raising $8.5 million under the ticker ‘NYR’. Nyrada was estab...

20 Dec 2019 - Clinical drug development company Noxopharm (ASX:NOX) has released DARRT-1 study clinical data which it says shows strong anti-cancer response in 47% of men with late…

The Boards of Noxopharm (NOX) and Nyrada have received full commitments for the $8.5 million IPO Noxopharm was advised by Lead Manager, Alto Capital that the IPO has been fully allocated and reconciliation of funds are underway Nyrada i...